Abstract
Introduction: This study aimed to investigate the association between proton pump inhibitors (PPIs) exposure and adverse outcomes in patients with inflammatory bowel disease (IBD). Methods: According to the guidelines outlined in the PRISMA and Meta-analysis of Observational Studies in Epidemiology (MOOSE), we conducted a comprehensive search of PubMed, Web of Science, Embase, and the Cochrane Library databases for relevant cohort and case-control studies comparing the incidence of adverse outcomes between IBD patients exposed to PPIs and those not exposed, from the inception of the databases to April 2024. The primary adverse outcomes analyzed included hospitalization and surgery. Results: Five studies, encompassing nearly 100,000 subjects, were included in this meta-analysis. The findings indicated that IBD patients exposed to PPIs had a significantly higher incidence of adverse outcomes compared to those not exposed (odds ratio [OR] = 1.24, 95% confidence interval [CI] = 1.07–1.44, p = 0.004), although it was low-quality evidence. This increased risk was observed in both ulcerative colitis (OR = 1.38, 95% CI = 1.04–1.83, p = 0.025) and Crohn’s disease (OR = 1.14, 95% CI = 1.02–1.29, p = 0.025). Additionally, the incidence of surgery was higher in IBD patients with PPI exposure (OR = 1.31, 95% CI = 1.02–1.68). However, the OR for hospitalization did not show a statistically significant difference (OR = 1.43, p = 0.244). Moreover, the use of glucocorticoids was more frequent among patients exposed to PPIs (OR = 1.16, 95% CI = 1.06–1.28, p = 0.001). Conclusion: PPI exposure may be associated with an increased risk of adverse outcomes in IBD patients, particularly a higher rate of surgery. Limited by various factors, the evidence is considered low quality.
Journal Section:
Small and Large Bowel: Systematic Review
References
1.
Molodecky
NA
, Soon
IS
, Rabi
DM
, Ghali
WA
, Ferris
M
, Chernoff
G
, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review
. Gastroenterology
. 2012
;142
(1
):46
–54.e42
; quiz e30. 2.
Park
KT
, Ehrlich
OG
, Allen
JI
, Meadows
P
, Szigethy
EM
, Henrichsen
K
, et al. The cost of inflammatory bowel disease: an initiative from the crohn’s&colitis foundation
. Inflamm Bowel Dis
. 2020
;26
:1
–10
. 3.
Chen
L
, Hu
K
, Cheng
C
, Hu
Q
, Zhang
L
, An
T
, et al. Risk of adverse outcomes in inflammatory bowel disease patients infected with SARS-CoV-2: a systematic review and meta-analysis
. Int J Colorectal Dis
. 2022
;37
(11
):2277
–89
. 4.
Singh
N
, Nugent
Z
, Singh
H
, Shaffer
SR
, Bernstein
CN
. Proton pump inhibitor use before and after a diagnosis of inflammatory bowel disease
. Inflamm Bowel Dis
. 2023
;29
(12
):1871
–8
. 5.
Choden
T
, Zhang
H
, Sakuraba
A
. Influence of proton pump inhibitor use on clinical outcomes of patients with inflammatory bowel disease
. Ann Med
. 2023
;55
(1
):2198775
. 6.
Lassalle
M
, Le Tri
T
, Bardou
M
, Biour
M
, Kirchgesner
J
, Rouby
F
, et al. Use of proton pump inhibitors in adults in France: a nationwide drug utilization study
. Eur J Clin Pharmacol
. 2020
;76
(3
):449
–57
. 7.
Xia
B
, He
Q
, Smith
FG
, Gkoutos
VG
, Nirantharakumar
K
, Kuo
ZC
, et al. Individualized prevention of proton pump inhibitor related adverse events by risk stratification
. Nat Commun
. 2024
;15
(1
):3591
. 8.
Juillerat
P
, Schneeweiss
S
, Cook
EF
, Ananthakrishnan
AN
, Mogun
H
, Korzenik
JR
. Drugs that inhibit gastric acid secretion may alter the course of inflammatory bowel disease
. Aliment Pharmacol Ther
. 2012
;36
(3
):239
–47
. 9.
Lu
TX
, Dapas
M
, Lin
E
, Peters
T
, Sakuraba
A
. The influence of proton pump inhibitor therapy on the outcome of infliximab therapy in inflammatory bowel disease: a patient-level meta-analysis of randomised controlled studies
. Gut
. 2021
;70
(11
):2076
–84
. 10.
Namazi
MR
, Jowkar
F
. A succinct review of the general and immunological pharmacologic effects of proton pump inhibitors
. J Clin Pharm Ther
. 2008
;33
(3
):215
–7
. 11.
Zedtwitz-Liebenstein
K
, Wenisch
C
, Patruta
S
, Parschalk
B
, Daxböck
F
, Graninger
W
. Omeprazole treatment diminishes intra- and extracellular neutrophil reactive oxygen production and bactericidal activity*
. Crit Care Med
. 2002
;30
(5
):1118
–22
. 12.
Page
MJ
, McKenzie
JE
, Bossuyt
PM
, Boutron
I
, Hoffmann
TC
, Mulrow
CD
, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
. BMJ
. 2021
;372
:n71
. 13.
Stroup
DF
, Berlin
JA
, Morton
SC
, Olkin
I
, Williamson
GD
, Rennie
D
, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group
. JAMA
. 2000
;283
(15
):2008
–12
. 14.
Stang
A
. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses
. Eur J Epidemiol
. 2010
;25
(9
):603
–5
. 15.
Guyatt
G
, Oxman
AD
, Akl
EA
, Kunz
R
, Vist
G
, Brozek
J
, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables
. J Clin Epidemiol
. 2011
;64
(4
):383
–94
. 16.
Shah
R
, Richardson
P
, Yu
H
, Kramer
J
, Hou
JK
. Gastric acid suppression is associated with an increased risk of adverse outcomes in inflammatory bowel disease
. Digestion
. 2017
;95
(3
):188
–93
. 17.
Fossmark
R
, Lirhus
SS
, Høivik
ML
. The impact of proton pump inhibitors on the course of ulcerative colitis: a cohort study of over 10,000 newly diagnosed patients in Norway
. Scand J Gastroenterol
. 2024
;59
(1
):46
–51
. 18.
Leonard
J
, Marshall
JK
, Moayyedi
P
. Systematic review of the risk of enteric infection in patients taking acid suppression
. Am J Gastroenterol
. 2007
;102
(9
):2047
–57
; quiz 2057. 19.
Issa
M
, Vijayapal
A
, Graham
MB
, Beaulieu
DB
, Otterson
MF
, Lundeen
S
, et al. Impact of Clostridium difficile on inflammatory bowel disease
. Clin Gastroenterol Hepatol
. 2007
;5
(3
):345
–51
. 20.
Axelrad
JE
, Joelson
A
, Green
PHR
, Lawlor
G
, Lichtiger
S
, Cadwell
K
, et al. Enteric infections are common in patients with flares of inflammatory bowel disease
. Am J Gastroenterol
. 2018
;113
(10
):1530
–9
. 21.
Manichanh
C
, Borruel
N
, Casellas
F
, Guarner
F
. The gut microbiota in IBD
. Nat Rev Gastroenterol Hepatol
. 2012
;9
(10
):599
–608
. 22.
Machiels
K
, Joossens
M
, Sabino
J
, De Preter
V
, Arijs
I
, Eeckhaut
V
, et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis
. Gut
. 2014
;63
(8
):1275
–83
. 23.
Fujimoto
T
, Imaeda
H
, Takahashi
K
, Kasumi
E
, Bamba
S
, Fujiyama
Y
, et al. Decreased abundance of Faecalibacterium prausnitzii in the gut microbiota of Crohn’s disease
. J Gastroenterol Hepatol
. 2013
;28
(4
):613
–9
. 24.
Wandall
JH
. Effects of omeprazole on neutrophil chemotaxis, super oxide production, degranulation, and translocation of cytochrome b-245
. Gut
. 1992
;33
(5
):617
–21
. 25.
Round
JL
, Mazmanian
SK
. The gut microbiota shapes intestinal immune responses during health and disease
. Nat Rev Immunol
. 2009
;9
(5
):313
–23
. 26.
Alkim
H
, Unal
S
, Okur
H
, Imir
T
. Omeprazole inhibits natural killer cell functions
. Dig Dis Sci
. 2008
;53
(2
):347
–51
. 27.
Bruno
G
, Zaccari
P
, Rocco
G
, Scalese
G
, Panetta
C
, Porowska
B
, et al. Proton pump inhibitors and dysbiosis: current knowledge and aspects to be clarified
. World J Gastroenterol
. 2019
;25
(22
):2706
–19
. 28.
Son
M
, Park
IS
, Kim
S
, Ma
HW
, Kim
JH
, Kim
TI
, et al. Novel potassium-competitive acid blocker, tegoprazan, protects against colitis by improving gut barrier function
. Front Immunol
. 2022
;13
:870817
. 29.
Abrahami
D
, McDonald
EG
, Schnitzer
ME
, Barkun
AN
, Suissa
S
, Azoulay
L
. Proton pump inhibitors and risk of colorectal cancer
. Gut
. 2022
;71
(1
):111
–8
. 30.
Imhann
F
, Bonder
MJ
, Vich Vila
A
, Fu
J
, Mujagic
Z
, Vork
L
, et al. Proton pump inhibitors affect the gut microbiome
. Gut
. 2016
;65
(5
):740
–8
. 31.
Greco
A
, Caviglia
GP
, Brignolo
P
, Ribaldone
DG
, Reggiani
S
, Sguazzini
C
, et al. Glucose breath test and Crohn’s disease: diagnosis of small intestinal bacterial overgrowth and evaluation of therapeutic response
. Scand J Gastroenterol
. 2015
;50
(11
):1376
–81
. © 2024 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024
You do not currently have access to this content.
